Evolving platform

Evolving platform
Colin Kerr
Colin Kerr
Published: Tuesday, May 1, 2018
LENSAR has received 510(k) clearance from the US Food and Drug Administration for the LENSAR Laser System with Streamline IV, expanding the platform’s capabilities to include the creation of the corneal pockets and flaps used in ophthalmic procedures treating presbyopia. “The continued expansion of capabilities with the LENSAR Laser System is the latest demonstration of our commitment to technological innovation,” said Nicholas Curtis, CEO of LENSAR. “It made sense to evolve our platform to support surgeons meeting the increasing patient demand with options for the treatment of presbyopia with corneal inlay devices.” http://www.lensar.com/
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...